

AHS Consensus Statement Guidelines Suggest Criteria for Acute Treatment with Gepants

Use of gepants for acute treatment of migraine is appropriate when all of the following criteria are met:

Prescriber

Must be prescribed/recommended by a licensed clinician

Patient

Must be at least 18 years of age

Medical history

Either of the following:

- Contraindications to or inability to tolerate triptans
- Inadequate response to 2 or more oral triptans, as determined by EITHER of the following:
 - Validated acute treatment patient-reported outcome questionnaire
 - Clinician attestation

Triptan and Gepant Side Effect Comparison (>2% in Clinical Trials)

Gepants rimegepant (r), ubrogepant (u), atogepant (a), and zavegepant (z) ¹⁻⁴	Triptans sumatriptan (s), rizatriptan (r), zolmitriptan (z), eletriptan (e), frovatriptan (f), naratriptan (n), almotriptan (a) ⁵⁻¹¹	
Nausea (a, u, r, z)	Nausea (z, r, e, n, a)	Asthenia (z, r, e)
Vomiting (z)	Dysphagia (z, e)	Dyspepsia (z, e, f)
Dry mouth (u)	Dry mouth (z, r, e, f, a)	Paresthesia (s, z, r, e, f)
Somnolence (u ,a)	Fatigue/somnolence (s, z, r, e, f, n)	Warm or cold sensations (s, z, f)
Decreased appetite (a)	Regional pain/abdominal pain (r, e, f)	Chest tightness (s, z, r, f)
Constipation (a)	Vertigo/dizziness (s, z, r, e, f, n)	Chest, throat or neck pressure (s, z, r, e, n)
Nasal discomfort (z)	Headache (r, e, f)	Flushing (e, f)
Taste disorders (z)	Sweating (z)	Palpitations (z)
Dizziness (a)		


1. Qulipta. Package insert. AbbVie.; 2023; 2. Nurtec ODT. Package insert. Pfizer Inc.; 2023; 3. Ubrelvy. Package insert. Allergan Pharmaceuticals International Limited; 2023; 4. Zavzpret. Package insert. Pfizer Inc.; 2023; 5. Imitrex. Package insert. GlaxoSmithKline; 2020; 6. Zomig. Package insert. Impax Pharmaceuticals; 2022; 7. Maxalt. Package insert. Organon & Co.; 2019; 8. Relpax. Package insert. Pfizer Inc.; 2020; 9. Frova. Package insert. Endo Pharmaceuticals Inc.; 2018; 10. Amerge. Package insert. GlaxoSmithKline; 2020; 11. Axert, Package insert. Janssen-Ortho, LLC; 2017

Constipation Is Not a Consistent Adverse Effect Across Gepants

- Constipation has an incidence of 3.41 per 100 person years in the migraine population vs 1.48 per 100 person years in the general population. About 1 in every 5 of these cases was rated as serious¹
- CGRP antagonism may reduce gastrointestinal motility and increase constipation risk²
- Atogepant (phase 3, double-blind, 12-week trial)³

Dose	Constipation (%)	No serious cases
Atogepant 10 mg (n = 221)	7.7%	
Atogepant 30 mg (n = 228)	7.0%	
Atogepant 60 mg (n = 211)	6.9%	
Placebo (n = 222)	0.5%	

- Constipation was not noted in other gepant trials,⁴ but was reported by 4.7% of 106 participants in a ubrogepant post-marketing cohort study⁵



- ✓ CGRP is widely expressed in the enteric nervous system
- ✓ CGRP receptors are found throughout the gastrointestinal system
- ✓ Blocking the CGRP receptor may reduce gastrointestinal motility
- ✓ Increased free CGRP binds to the amylin 1 receptor, which can contribute to constipation²